@article {Caveliers1647, author = {Vicky Caveliers and Hendrik Everaert and Christy S. John and Tony Lahoutte and Axel Bossuyt}, title = {Sigma Receptor Scintigraphy with N-[2-(1'-Piperidinyl)Ethyl]-3-123I-Iodo-4-Methoxybenzamide of Patients with Suspected Primary Breast Cancer: First Clinical Results }, volume = {43}, number = {12}, pages = {1647--1649}, year = {2002}, publisher = {Society of Nuclear Medicine}, abstract = {The aim of this study was to investigate the potential of a new iodobenzamide, N-[2-(1'-piperidinyl)ethyl]-3-123I-iodo-4-methoxybenzamide (P-123I-MBA), to visualize primary breast tumor in humans in vivo. Tumor accumulation of benzamides is based on a preferential binding to sigma receptors that are overexpressed on breast cancer cells. Methods: P-123I-MBA (148{\textendash}185 MBq) was administered to 12 patients with a mammographically suspicious breast mass. Two hours after administration, whole-body and spot images of the healthy and the diseased breast were obtained. Results: A focal increased tracer accumulation was observed in 8 of 10 patients with histologically confirmed breast cancer (mean tumor-to-background ratio, 2.04). No uptake was seen in a case of lymphatic adenitis. Conclusion: This preliminary patient study shows that P-123I-MBA accumulates in most breast tumors in vivo. Future work should focus on the relationship between P-123I-MBA uptake and the proliferative activity of cells to anticipate use of this technique as a tool to noninvasively assess the degree of tumor proliferation.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/43/12/1647}, eprint = {https://jnm.snmjournals.org/content/43/12/1647.full.pdf}, journal = {Journal of Nuclear Medicine} }